India Monoclonal Antibodies Market By Type (Murine, Chimeric, Humanized, Human), By Application (Cancer, Cardiac/Cardiovascular, Neurological, Others), By Production (In vitro, In vivo), By Biomanufacturing (Originator, CMO), By End User (Hospitals, Research Laboratories, Others), By Region, Competition, Forecast and Opportunities, 2020-2030F

Market Overview

India Monoclonal Antibodies Market was valued at USD 208.58 Million in 2024 and is expected to reach USD 287.94 Million by 2030 with a CAGR of 5.72% during the forecast period.

Monoclonal antibodies (mAbs) are laboratory-engineered molecules designed to target specific antigens and help treat diseases such as cancer, autoimmune disorders, and infectious conditions. In India, the monoclonal antibodies market is growing rapidly due to advancements in biotechnology, rising healthcare demand, and increasing adoption of targeted therapies. The development of biosimilars by Indian pharmaceutical companies has improved affordability and accessibility, while partnerships with global firms and expanding clinical trials are further supporting market growth. However, high treatment costs and strict regulatory requirements remain major challenges. With growing focus on precision medicine, improved healthcare infrastructure, and government support, India’s monoclonal antibodies market is expected to witness significant expansion in the coming years.

Key Market Drivers

Growing Prevalence of Chronic Diseases

• The rising prevalence of chronic diseases in India is a major factor driving growth in the monoclonal antibodies market, as conditions such as cancer, cardiovascular diseases, autoimmune disorders, and diabetes are becoming more common due to lifestyle changes, population aging, and environmental influences. This expanding disease burden is increasing the need for advanced biologic therapies that can deliver more precise and effective treatment outcomes across long-term and complex disease categories.

• Recent evidence from the Longitudinal Ageing Survey in India highlights the depth of this challenge, showing that 21% of the elderly population lives with at least one chronic condition, with higher prevalence in urban areas at 29% compared with 17% in rural areas. Hypertension and diabetes together account for nearly 68% of chronic diseases among older adults, while cardiovascular diseases affect 37% of people aged 75 and above, alongside rising bone, joint, and chronic lung disease incidence.

• As these disorders affect a larger share of India’s population, demand for monoclonal antibodies is rising because these therapies can target the underlying biological drivers of disease with greater precision than many conventional treatments. This makes them especially valuable in cancer and autoimmune disorders, where long-term disease control, specialized care, and reduced damage to healthy tissue are critical for improving outcomes and supporting continuous treatment strategies.

• The growing burden of chronic diseases is also increasing healthcare system focus on innovative and specialized treatment approaches, which is further accelerating demand for monoclonal antibody therapies in India. As the need for effective, targeted, and durable therapies intensifies, the market is expected to expand significantly, creating strong opportunities for pharmaceutical companies to develop, introduce, and commercialize new mAb-based products across multiple therapeutic areas.

Growing Demand for Targeted Therapies

• The growing demand for targeted therapies is a key growth driver for the monoclonal antibodies market in India, as the healthcare sector steadily shifts toward precision medicine and treatment approaches that address disease mechanisms directly rather than only controlling symptoms. Monoclonal antibodies are at the center of this transition because they can specifically bind to selected molecules or cells linked to particular diseases, improving treatment precision and expanding therapeutic value.

• The clinical need for targeted therapies is particularly evident in oncology, where disease burden remains high and outcomes often depend on early, effective, and highly specific intervention. According to the Indian Council of Medical Research, for every two women diagnosed with breast cancer in India, one dies from the disease, while nearly 2,500 people die each day from tobacco-related illnesses. Oral and lung cancers in men and cervix and breast cancers in women account for more than 50% of cancer-related deaths.

• Targeted therapies are increasingly preferred for complex conditions such as cancer, autoimmune diseases, and other chronic illnesses because they offer more focused treatment with less collateral damage to healthy tissue. In cancer care, for example, monoclonal antibodies can be engineered to bind specific antigens on tumor cells, enabling more selective treatment delivery, improving therapeutic effectiveness, and helping reduce side effects that are often associated with broader systemic therapies.

• As both patients and healthcare professionals increasingly seek therapies that provide better outcomes, higher precision, and fewer adverse effects, demand for monoclonal antibodies continues to grow across India. This rising preference for personalized and targeted treatment is supporting broader market expansion and encouraging pharmaceutical companies to invest in the development and commercialization of new mAb-based therapies for a wider range of oncological, autoimmune, and chronic disease applications.

Download Free Sample Report

Key Market Challenges

Quality Assurance and Manufacturing

• Quality assurance and manufacturing remain a major challenge in the India monoclonal antibodies market because mAb production depends on tightly controlled cell culture, purification, fill-finish operations, sterility management, analytical testing, and documentation systems that must perform consistently from development stage through full commercial supply. This makes biologics manufacturing significantly more complex and risk-sensitive than conventional pharmaceutical production.

• Even minor deviations in contamination control, process reproducibility, environmental monitoring, or batch release standards can affect monoclonal antibody quality, product consistency, and regulatory acceptability. Because biologics are highly sensitive to manufacturing conditions, Indian companies must maintain validated systems and robust quality infrastructure to ensure compliance, reduce batch failures, and protect market credibility in both domestic and export markets.

• The challenge becomes more intense as Indian manufacturers expand into global biosimilar and biologics markets, where facilities must comply with overlapping GMP expectations from regulators such as the USFDA and EMA while also ensuring uninterrupted access to critical raw materials, single-use systems, and technically trained bioprocess personnel. Scaling capacity therefore requires capital, experienced teams, and inspection-ready quality systems.

• The operational complexity of compliant large-scale biologics manufacturing is evident from Biocon Biologics’ disclosure that a combined USFDA cGMP and pre-licensing inspection at its Biocon Park facility in Bengaluru covered 6 biologics manufacturing units, 5 analytical quality control laboratories, 4 microbiology laboratories, and 2 warehouses, highlighting the breadth of infrastructure needed to support monoclonal antibody production in India.

Cost and Affordability

• Cost and affordability remain a major barrier in the India monoclonal antibodies market because mAb therapies involve expensive biologic manufacturing, temperature-controlled logistics, hospital-based administration, specialist supervision, and often prolonged treatment regimens. These factors substantially increase the total cost of care and create access challenges in a healthcare system where affordability strongly influences treatment uptake and continuity.

• This issue is particularly important in India’s price-sensitive healthcare environment, where insurance penetration remains limited and out-of-pocket spending is still high for many patients. Even when monoclonal antibodies offer strong clinical benefits, the financial burden can delay treatment initiation, influence physician prescribing decisions, and reduce patient compliance, especially in oncology and chronic disease settings that require repeated dosing over time.

• Although biosimilars have improved access by lowering prices relative to originator brands, overall treatment costs often remain high enough to restrict wider market penetration. This means affordability continues to shape commercial demand, competitive positioning, and real-world usage of biologic therapies in India more strongly than in several mature monoclonal antibody markets with broader reimbursement coverage.

• Pricing data presented at ISPOR illustrates this challenge clearly, showing that originator trastuzumab in India was priced at roughly Rs 55,000 to Rs 75,000 per 440" mg"  vial in private pharmacies, while biosimilars were available at around Rs 18,000 to Rs 30,000 per vial. Although this reflects a price reduction of about 50% to 70%, therapy still remains costly for many patients.

Key Market Trends

Rising Focus on Biosimilars

• Biosimilars are becoming a central growth driver in India’s monoclonal antibodies market because they are biologic products designed to closely resemble already approved reference therapies while being offered at a lower cost than branded originators. This cost advantage is especially important in India, where affordable access to advanced biologic treatment can significantly improve therapy uptake among low- and middle-income patient populations.

• The long-term opportunity is expanding rapidly as a study commissioned by the Department of Pharmaceuticals projected that by 2030, patents for 24 major drugs will expire, including globally recognized therapies such as Humira (adalimumab), Keytruda (pembrolizumab), Opdivo (nivolumab), Ibrance (palbociclib), and Symbicort (budesonide). These patent expiries are expected to unlock a market worth more than USD 250" billion" , creating strong room for Indian companies to launch biosimilar and generic alternatives.

• India’s commercial position is particularly favorable because more than 20 high-value drugs with combined annual sales of around USD 250" billion"  are expected to go off-patent, allowing domestic manufacturers to expand into large global therapy segments. This opens substantial opportunities for Indian pharmaceutical and biologics companies to strengthen their presence in oncology, immunology, and other chronic disease categories through cost-competitive biosimilar development.

• The regulatory environment in India has also become more supportive of biosimilar growth, with the Central Drugs Standard Control Organisation (CDSCO) streamlining approval processes and improving the pathway for product development and commercialization. In addition, government support for biosimilar research and development has helped accelerate this segment, making India a more attractive base for innovation, clinical advancement, and large-scale manufacturing of mAb-related therapies.

• Biosimilar applications in India were initially concentrated in oncology and immunology, but the market is now expanding across a broader set of therapeutic areas including rheumatology, diabetes, and dermatology. This widening clinical relevance is boosting demand because it allows biosimilars to address a more diverse patient base, support treatment affordability across multiple specialties, and strengthen the overall role of biologics in India’s evolving healthcare landscape.

• Recent product development milestones highlight the pace of progress in this segment. For instance, in March 2024, Aurobindo Pharma Ltd announced that its wholly owned subsidiary, CuraTeQ Biologics Pvt Ltd, reported positive Phase-1 trial results for its Omalizumab biosimilar (BP11), showing favorable comparison with the reference product Xolair sourced from the U.S. and EU. Omalizumab is a monoclonal antibody used in the treatment of asthma and hives.

• India’s leadership in biosimilar production is not limited to domestic healthcare needs, as the country is also emerging as an important supplier to international markets including Europe, the U.S., and several emerging economies. This global potential strengthens India’s role in the worldwide biologics value chain and creates additional export, manufacturing, and partnership opportunities for companies active in monoclonal antibody development.

• As biosimilar adoption continues to rise, affordability, accessibility, and clinical effectiveness will remain the most important factors shaping the future of India’s monoclonal antibodies market. Their growing role in expanding patient access, reducing treatment costs, supporting innovation, and enabling wider therapeutic coverage makes biosimilars a key pillar of future market growth and competitive development in the Indian mAb industry.

Segmental Insights

Type Insights

Based on Type, the Human emerged as the fastest growing segment in the Indian market for Monoclonal Antibodies during the forecast period. Fully human monoclonal antibodies (mAbs) are engineered to target specific molecules or cells involved in disease processes with a high degree of precision. This targeted approach enables more effective treatments, especially for complex conditions like cancer, autoimmune disorders, and infectious diseases. By focusing exclusively on the relevant disease-causing factors, human mAbs deliver superior therapeutic outcomes compared to other types, such as murine or chimeric mAbs. Since human mAbs are derived entirely from human sources, they are less likely to trigger immune reactions, making them safer and better tolerated by patients, which enhances their appeal in clinical settings.

Advances in biotechnology, including the use of transgenic mice and phage display techniques, have facilitated the development of high-quality fully human antibodies, increasing their availability and cost-effectiveness. These innovations are contributing to the rapid expansion of the human mAb market. Regulatory agencies, such as the U.S. FDA and the EMA, are increasingly favorable towards fully human mAbs, offering faster approval processes due to their lower immunogenicity and superior safety profile. This regulatory confidence is fostering further investment and development in human mAbs.

As the healthcare sector moves towards personalized medicine, human mAbs are becoming central to this shift, offering highly targeted therapies tailored to an individual's genetic profile or specific disease mechanisms. This aligns with the growing demand for treatments that are more precise, effective, and have fewer side effects. While initially used primarily in oncology, the applications of human mAbs are now expanding into areas like autoimmune disorders, infections, and neurological conditions. This broadening of therapeutic uses is significantly increasing their market potential and growth opportunities.

Application Insights

Based on Application, Cancer emerged as the dominating segment in the Indian market for Monoclonal Antibodies in 2024. India has experienced an increase in cancer diagnoses, with a growing number of cases each year. Common types of cancer, including breast cancer, lung cancer, colorectal cancer, and head and neck cancers, are becoming more widespread, driving demand for advanced treatments like monoclonal antibodies. Breast cancer is the most prevalent cancer among women in India, representing 28.2% of all female cancers, with approximately 216,108 new cases estimated in 2022.

Monoclonal antibodies have proven highly effective in cancer treatment, particularly by modulating the immune system and targeting tumor cells. These therapies have become a standard approach for various cancers, offering better survival rates and quality of life compared to traditional treatments like chemotherapy and radiation. Both international and Indian pharmaceutical companies are making significant investments in the development of mAb-based cancer therapies. The emphasis on innovative, targeted cancer treatments is driving growth in the oncology sector. As India’s healthcare infrastructure improves, and the cost of monoclonal antibodies decreases partly due to the rise of biosimilars—oncology continues to be the largest and fastest-growing therapeutic area for mAb treatments.

Download Free Sample Report

Regional Insights

• South India emerged as the dominant region in India’s monoclonal antibodies market in 2024, led by Tamil Nadu, Karnataka, Andhra Pradesh, and Kerala, where advanced healthcare infrastructure, specialized cancer centers, hospitals, and research facilities support strong therapy administration and market expansion.

• Cities such as Hyderabad, widely recognized as “Genome Valley,” and Bengaluru serve as major pharmaceutical and biotechnology hubs, supported by strong research and development capabilities in monoclonal antibody development and production, which reinforce the region’s importance in India’s evolving mAb landscape.

• The presence of leading pharmaceutical and biosimilar companies has significantly strengthened South India’s leadership in the monoclonal antibodies market, enabling higher production capabilities, deeper industry specialization, and faster commercialization of therapies designed for cancer and other complex disease indications.

• South India also leads the country in monoclonal antibody-related clinical trials, as its healthcare institutions are well equipped to manage emerging treatments, thereby accelerating research activity, improving patient access, and supporting quicker adoption of newer monoclonal antibody therapies across the region.

• The region further benefits from government initiatives that enhance healthcare access and promote advanced treatments, while top medical and pharmaceutical universities produce a highly skilled biotechnology and molecular biology workforce, strengthening the pharmaceutical sector and sustaining monoclonal antibody market growth.

Recent Development

• In June 2025, Serum Institute of India signed an MoU with the Drugs for Neglected Diseases initiative to accelerate development of an affordable monoclonal antibody treatment for dengue, a partnership aimed at low- and middle-income countries. The collaboration was important because SII had already completed preclinical work and Phase I-II studies on the candidate and was leading a pivotal Phase III trial in India for licensure at the time of the announcement. The two partners also said they would form a joint project team to advance further Phase III trials and work toward registration and deployment in India and other dengue-endemic countries if safety and efficacy are confirmed.

• In May 2025, India could begin human trials for the novel Nipah monoclonal antibody MBP1F5 during 2025, pending regulatory clearance. The program was backed by CEPI, with ServareGMP leading the trial effort and Mapp Biopharmaceutical providing support, while local clinical research networks in India and Bangladesh were expected to participate. This counted as a breakthrough innovation because preclinical studies had already shown the antibody to be highly potent against Nipah virus, preventing viral entry into host cells and remaining safe across tested dose levels.

• In November 2025, the Indian Council of Medical Research invited expressions of interest from Indian companies and manufacturers to develop and produce monoclonal antibodies against Nipah viral disease after successful animal trials of an indigenous candidate. The initiative was framed as an effort to build India’s own domestic monoclonal-antibody platform for outbreak preparedness, with ICMR stating that it and its institutes would provide technical guidance and support throughout research, development, and commercialization. The development stood out because it shifted monoclonal-antibody work from laboratory success toward structured industry collaboration and manufacturing readiness inside India.

• In December 2025, Sun Pharma launched ILUMYA in India for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ILUMYA is a humanized monoclonal antibody, and the launch expanded India’s access to an IL-23 inhibitor that Sun Pharma said had already been marketed in 35 countries before entering the Indian market. This was a meaningful product-launch development because it added a newer biologic option to India’s immunology and dermatology treatment landscape rather than another conventional small-molecule therapy.

Key Market Players

• Dr. Reddy's Laboratories Ltd.
• Bristol Myers Squibb India Pvt. Ltd.
• Roche India Pvt. Ltd.
• Intas Pharmaceuticals Limited
• Merck India
• Eli Lilly, and Company (India) Private Limited
• Biocon Limited
• AstraZeneca India Pvt. Ltd.
• Pfizer Limited

Report Scope:

In this report, the India Monoclonal Antibodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• India Monoclonal Antibodies Market, By Type:

o   Murine

o   Chimeric

o   Humanized

o   Human

• India Monoclonal Antibodies Market, By Application:

o   Cancer

o   Cardiac/Cardiovascular

o   Neurological

o   Others  

• India Monoclonal Antibodies Market, By Production:

o   In vitro

o   In vivo  

• India Monoclonal Antibodies Market, By Biomanufacturing:

o   Originator

o   CMO  

• India Monoclonal Antibodies Market, By End User:

o   Hospitals

o   Research Laboratories

o   Others  

• India Monoclonal Antibodies Market, By Region:

o   West India

o   North India

o   South India

o   East India

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the India Monoclonal Antibodies Market.

Available Customizations:

India Monoclonal Antibodies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

India Monoclonal Antibodies Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]